AGENDA

7:30am  NETWORKING BREAKFAST

8:00am  WELCOME & TCF-001 TRACK OVERVIEW
Jim Palma, Executive Director, TargetCancer Foundation

8:30am  PATIENT KEYNOTE
Allen Chankowsky, Author, “On the Other Side of Terminal”

8:50am  SCIENTIFIC KEYNOTE
Precision Genomics and Immunotherapy for Rare Cancers: The N-of-1 Era
Razelle Kurzrock, MD, Medical College of Wisconsin

9:25am  SESSION 1: CLINICAL TRIALS
Tumor Agnostic Therapies and Clinical Trials for Rare Cancers
Vivek Subbiah, MD, MD Anderson Cancer Center

9:55am  MORNING BREAK

10:10am  MOLECULAR TUMOR BOARD
TCF-001 TRACK Molecular Tumor Board

10:50am  SESSION 2: GERMLINE AND SOMATIC GENETICS
Genetic Counseling and Testing in Rare Cancers
Catherine Skefos, MA, MS, CGC, MD Anderson Cancer Center

Somatic Genetics and Molecular Testing
Julia Elvin, MD, PhD, Foundation Medicine

Rare Cancer Types: Discovery of Novel Genetics
Jorge Reis-Filho, MD, PhD, Memorial Sloan Kettering Cancer Center

12:30pm  NETWORKING LUNCH
AGENDA

1:20pm  **SESSION 3: BIOMARKERS AND EMERGING TECHNOLOGIES**
AI-Driven Computational Pathology
Faisal Mahmood, PhD, *Brigham and Women’s Hospital*

Epigenomic Technologies to Study Rare Cancers
Miguel Rivera, MD, *Massachusetts General Hospital*

Biomarker Driven Early Intervention: PD-1 Blockade as Curative-Intent Therapy in Locally Advanced Mismatch Repair Deficient Rectal Cancer
Andrea Cercek, MD, *Memorial Sloan Kettering Cancer Center*

3:00pm  **SESSION 4: PATIENT DRIVEN DATA DISCOVERY**
The Angiosarcoma Project Story
Corrie Painter, PhD, *Broad Institute of MIT and Harvard*

3:30pm  **SESSION 5: PANEL AND GUIDED DISCUSSION**
Challenges and barriers to adoption of biomarker testing
Deborah Morosini, MD, *Honey Locust Advisers LLC*
Susan Spinosa, *NTRKers*